{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:06:56Z","timestamp":1785323216591,"version":"3.55.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Genitourinary Medical Oncologists of Canada","award":["2017 GUMOC Grant"],"award-info":[{"award-number":["2017 GUMOC Grant"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Non-schistosomiasis related-squamous cell carcinoma of urinary bladder (NSR-SCCUB) is a rare tumor subtype distinct from urothelial carcinoma (UC). Studies assessing molecular biomarkers in bladder cancer have generally focused on UC, and genomic data of NSR-SCCUB is limited. We aim to provide additional insight into the molecular underpinnings of this rare entity.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>NSR-SCCUB patients were identified retrospectively at Princess Margaret Cancer Centre between 2002 and 2017. Demographics, disease characteristics, therapeutic approaches, and outcomes were collected. Tissue samples were interrogated using the Oncomine Comprehensive Assay v3 (ThermoFisher). Kaplan-Meier method was used to estimate the disease-free survival and overall survival (OS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 11 patients with NSR-SCCUB were identified between 2002 and 2017 with adequate tissue samples. Median age was 71 years (45\u201386), predominantly male (63.6%). At time of diagnosis, 9 patients (81.8%) had muscle-invasive disease, 1 (9.1%) had non-muscle invasive, and 1 (9.1%) had advanced disease. Nine (81.8%) patients had radical cystectomy and pelvic lymph nodes dissection. Eight (72.7%) patients had pT3 or pT4 with N0, and 5 (45.5%) were grade 3. Median OS was 12.5 months (95% CI 7.7\u201317.2 months). Single nucleotide variants or insertion\/deletions were identified in <jats:italic>TP53<\/jats:italic>, <jats:italic>TERT<\/jats:italic>, <jats:italic>PIK3CA<\/jats:italic>, <jats:italic>PTEN<\/jats:italic>, <jats:italic>CREBBP<\/jats:italic>, FBXW<jats:italic>7<\/jats:italic>, <jats:italic>and FGFR3<\/jats:italic>. Amplifications were found in <jats:italic>CCND1<\/jats:italic>, and <jats:italic>EGFR<\/jats:italic>.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>NSR-SCCUB has potentially actionable genomic alterations with anticancer agents and many of these aberrations are also seen in UC. The recruitment of NSR-SCCUB patients harboring such mutations should be considered in biomarker driven urinary bladder cancer studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0259272","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:35:20Z","timestamp":1638383720000},"page":"e0259272","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study"],"prefix":"10.1371","volume":"16","author":[{"given":"Esmail M.","family":"Al-ezzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary W.","family":"Veitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer H.","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus H.","family":"Van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamini","family":"Selvarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Fallah-rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2363-8707","authenticated-orcid":true,"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"9","key":"pone.0259272.ref001","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1503\/cmaj.191292","article-title":"Projected estimates of cancer in Canada in 2020","volume":"192","author":"DR Brenner","year":"2020","journal-title":"Cmaj"},{"issue":"6 Suppl 4","key":"pone.0259272.ref002","first-page":"S193","article-title":"Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer","volume":"3","author":"V Chalasani","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"pone.0259272.ref003","first-page":"1","article-title":"Biomarkers for bladder cancer management: present and future","volume":"2","author":"F Ye","year":"2014","journal-title":"Am J Clin Exp Urol"},{"issue":"2","key":"pone.0259272.ref004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2004.04588.x","article-title":"Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment","volume":"93","author":"AA Shokeir","year":"2004","journal-title":"BJU Int"},{"issue":"2","key":"pone.0259272.ref005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-5347(01)64487-2","article-title":"Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases","volume":"158","author":"MA Ghoneim","year":"1997","journal-title":"J Urol"},{"issue":"3","key":"pone.0259272.ref006","first-page":"733","article-title":"Expression of cytokeratin 7, 20, 14 in urothelial carcinoma and squamous cell carcinoma of the Egyprian urinary bladder cancer","volume":"44","author":"O Hammam","year":"2014","journal-title":"J Egypt Soc Parasitol"},{"issue":"2","key":"pone.0259272.ref007","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clinbiochem.2004.09.004","article-title":"HER2\/neu expression in bladder cancer: relationship to cell cycle kinetics","volume":"38","author":"S Eissa","year":"2005","journal-title":"Clin Biochem"},{"issue":"1","key":"pone.0259272.ref008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1464-410X.2010.09854.x","article-title":"Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression","volume":"108","author":"R Youssef","year":"2011","journal-title":"BJU Int"},{"issue":"3","key":"pone.0259272.ref009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.aju.2016.07.001","article-title":"Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches","volume":"14","author":"JW Martin","year":"2016","journal-title":"Arab J Urol"},{"issue":"9","key":"pone.0259272.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.03.023","article-title":"Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder","volume":"34","author":"K Spradling","year":"2016","journal-title":"Urol Oncol"},{"issue":"4","key":"pone.0259272.ref011","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1464-410X.2005.05327.x","article-title":"Non-transitional cell bladder carcinomas","volume":"95","author":"A Manunta","year":"2005","journal-title":"BJU Int"},{"issue":"4","key":"pone.0259272.ref012","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10552-007-9104-7","article-title":"The changing patterns of bladder cancer in Egypt over the past 26 years","volume":"19","author":"AS Felix","year":"2008","journal-title":"Cancer Causes Control"},{"issue":"5b","key":"pone.0259272.ref013","first-page":"3865","article-title":"The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy","volume":"26","author":"E Kastritis","year":"2006","journal-title":"Anticancer Res"},{"key":"pone.0259272.ref014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2407-11-16","article-title":"Can Bcl-XL expression predict the radio sensitivity of bilharzial-related squamous bladder carcinoma? A prospective comparative study","volume":"11","author":"AM Abdel Raheem","year":"2011","journal-title":"BMC Cancer"},{"issue":"4","key":"pone.0259272.ref015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cncr.22853","article-title":"Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience","volume":"110","author":"W Kassouf","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"pone.0259272.ref016","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"CN Sternberg","year":"1989","journal-title":"Cancer"},{"key":"pone.0259272.ref017","unstructured":"The Genome Aggregation Database (gnomAD v2.1.1) 2019 [Available from: https:\/\/gnomad.broadinstitute.org\/."},{"issue":"7809","key":"pone.0259272.ref018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"KJ Karczewski","year":"2020","journal-title":"Nature"},{"issue":"5","key":"pone.0259272.ref019","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/modpathol.2016.53","article-title":"High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder","volume":"29","author":"M Cowan","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"pone.0259272.ref020","first-page":"171","article-title":"Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods","volume":"8","author":"ML Lu","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"9","key":"pone.0259272.ref021","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4161\/cc.8.9.8255","article-title":"PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches","volume":"8","author":"G Ligresti","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"pone.0259272.ref022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-018-0857-2","article-title":"FBXW7: a critical tumor suppressor of human cancers","volume":"17","author":"C-H Yeh","year":"2018","journal-title":"Mol Cancer"},{"issue":"13","key":"pone.0259272.ref023","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gad.14.13.1553","article-title":"CBP\/p300 in cell growth, transformation, and development","volume":"14","author":"RH Goodman","year":"2000","journal-title":"Genes Dev"},{"issue":"5","key":"pone.0259272.ref024","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"MS Song","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"924","key":"pone.0259272.ref025","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/pmj.78.924.584","article-title":"Epidermal growth factor receptor and bladder cancer","volume":"78","author":"AJ Colquhoun","year":"2002","journal-title":"Postgrad Med J"},{"issue":"1","key":"pone.0259272.ref026","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/modpathol.2013.125","article-title":"CCND1\/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response","volume":"27","author":"R Seiler","year":"2014","journal-title":"Mod Pathol"},{"issue":"2","key":"pone.0259272.ref027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1308\/rcsann.2016.0343","article-title":"Risk factors for development of primary bladder squamous cell carcinoma","volume":"99","author":"KV Manley","year":"2017","journal-title":"Ann R Coll Surg Engl"},{"issue":"2_suppl","key":"pone.0259272.ref028","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/jco.2016.34.2_suppl.423","article-title":"Molecular profiling of non-urothelial bladder cancer: Adenocarcinoma and squamous cell carcinoma","volume":"34","author":"DM Geynisman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"pone.0259272.ref029","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2019.37.7_suppl.399","article-title":"Non-urothelial bladder cancer: Genomic alterations and patient outcomes","volume":"37","author":"F Anari","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"pone.0259272.ref030","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.humpath.2009.03.005","article-title":"Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases","volume":"40","author":"CC Guo","year":"2009","journal-title":"Hum Pathol"},{"issue":"1","key":"pone.0259272.ref031","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clgc.2014.07.010","article-title":"Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin","volume":"13","author":"SZ Millis","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"pone.0259272.ref032","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/path.1481","article-title":"High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer","volume":"201","author":"BM Zaharieva","year":"2003","journal-title":"J Pathol"},{"issue":"4","key":"pone.0259272.ref033","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Y Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0259272.ref034","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cjp2.163","article-title":"Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment","volume":"6","author":"S Wang","year":"2020","journal-title":"J Pathol Clin Res"},{"issue":"2","key":"pone.0259272.ref035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"PH Kim","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"pone.0259272.ref036","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/0008-5472.CAN-12-1726","article-title":"PIK3CA mutation H1047R is associated with response to PI3K\/AKT\/mTOR signaling pathway inhibitors in early-phase clinical trials","volume":"73","author":"F Janku","year":"2013","journal-title":"Cancer Res"},{"issue":"44","key":"pone.0259272.ref037","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1038\/s41388-020-01465-y","article-title":"EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer","volume":"39","author":"M Rose","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"pone.0259272.ref038","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/21655979.2021.1915725","article-title":"The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer","volume":"12","author":"S Wan","year":"2021","journal-title":"Bioengineered"},{"issue":"5","key":"pone.0259272.ref039","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5347(05)66332-X","article-title":"Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2","volume":"165","author":"A Haitel","year":"2001","journal-title":"J Urol"},{"issue":"1","key":"pone.0259272.ref040","first-page":"568","article-title":"Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis","volume":"15","author":"L Zheng","year":"2018","journal-title":"Oncol Lett"},{"issue":"2","key":"pone.0259272.ref041","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.juro.2014.08.109","article-title":"Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma","volume":"193","author":"RF Youssef","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"pone.0259272.ref042","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000447140","article-title":"Expression of Epidermal Growth Factor Receptor and Transforming Growth Factor Alpha in Cancer Bladder","volume":"9","author":"AA Badawy","year":"2017","journal-title":"Schistosomal and Non-Schistosomal. Curr Urol"},{"issue":"4","key":"pone.0259272.ref043","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/172460080301800406","article-title":"Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder","volume":"18","author":"M El-Kenawy Ael","year":"2003","journal-title":"Int J Biol Markers"},{"issue":"2","key":"pone.0259272.ref044","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.humpath.2003.10.006","article-title":"Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2\/neu, and proliferation (MIB-1)","volume":"35","author":"KM Badr","year":"2004","journal-title":"Hum Pathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:35:59Z","timestamp":1638383759000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259272"}},"subtitle":[],"editor":[{"given":"Xin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0259272","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}